Up-regulation of survivin mRNA might be a marker for non-invasive detection of non-small cell lung cancer rather than for prognosis

Anticancer Research

Volumn 28, Issue 3 A, 2008, Pages 1525-1529

  Warnecke Eberz, Ute ^a   Baldus, Stephan E ^b   Bollschweiler, Elfriede ^a   Hoelscher, Arnulf H ^a   Metzger, Ralf ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

BIRC5; Gene expression; Lung cancer; Realtime RT PCR; Survivin; Tumor marker

Indexed keywords

MESSENGER RNA; SURVIVIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN INDUCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 45949091975     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ and Thun MJ: Cancer statistics 2005. CA Cancer J Clin 55: 10-30, 2005.
2. World Health Organization: The World Health Organization histologic typing of lung tumors. Am J Clin Pathol 77: 123-136, 1982.
3. Bulzebruck H, Bopp R, Drings P, Bauer E, Krysa S, Probst G, van Kaick G, Muller KM and Vogt-Moykopf I: New aspects in the staging of lung cancer. Prospective validation of the International Union Against Cancer TNM classification. Cancer 70: 1102-1110, 1992.
4. Mountain CF: The international system for staging lung cancer. Semin Surg Oncol 18: 106-115, 2000.
5. AC Society: Cancer Facts & Figures 2006. Atlanta, American Cancer Society, 2006.
6. Rosell R, Felip E, Garcia-Campelo R and Balana C: The biology of non-small-cell lung cancer: identifying new targets for rational therapy. Lung Cancer 46: 135-148, 2004.
7. Herbst RS, Onn A and Sandler A: Angiogenesis and lung cancer: prognostic and therapeutic implications. J Clin Oncol 23: 3243-3256, 2005.
8. Meyerson M, Franklin WA and Kelley MJ: Molecular classification and molecular genetics of human lung cancers. Semin Oncol 31: 4-19, 2004.
9. Singhal S, Vachani A, Antin-Ozerkis D, Kaiser LR and Albelda SM: Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin Cancer Res 11: 3974-3986, 2005.
10. Shin S, Sung B-J, Cho Y-S, Kim H-J, Ha N-C, Hwang J-I, Chung C-W, Jung Y-K and Oh B-H: An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 40: 1117-1123, 2001.
11. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC and Altieri DC: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 496: 580-584, 1998.
12. Adams RR, Carmena M and Earnshaw WC: Chromosomal passengers and the (aurora) ABCs of mitosis. Trends Cell Biol 11: 49-54, 2001.
13. Olie RA, Simoes-Wust AP, Baumann B, Leech SH, Fabbro D, Stahel RA and Zangemeister-Wittke U: A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 60: 2805-2809, 2000.
14. Velculescu VE, Madden SL, Zhang L, Lash AE, Yu J, Rago C, Lal A, Wang CJ, Beaudry GA, Ciriello KM, Cook BP, Dufault MR, Ferguson AT, Gao Y, He TC, Herme King H, Hiraldo SK, Hwang PM, Lopez MA, Lyderer HF, Mathews B, Petroziello JM, Polyak K, Zawel L, Kinzler KW et al: Analysis of human transcriptomes. Nat Genet 23: 387-388, 1999.
15. Li F: Survivin study: what is the next wave? J Cell Physiol 197: 8-29, 2003.
16. Monzo M. Rosell R, Felip E, Astudillo J, Sanchez JJ, Maestre J, Martin C, Font A, Barnadas A and Abad A: A novel antiapoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol 17: 2100-2104, 1999.
17. Ikehara M, Oshita F, Kameda Z, Hirozuki I, Ohgane N, Suyuki R, Saito H, Zamada K, Noda K and Mitsuda A: Expression of survivin correlated with vessel invasion is a marker of poor prognosis in small adenocarcinoma of the lung. Oncol Rep 9: 838-838, 2002.
18. Hofman H-S, Simm A, Hammer A, Silber R-E and Bartling B: Expression of inhibitors of apoptosis (IAP) proteins in non-small cell human lung cancer. J Cancer Res Clin Oncol 128: 554-560, 2002.
19. Falleni M, Pellegrini C, Marchetti A, Ooprani B, Buttitta F, Barassi F, Santambrogio L, Coggi G and Bosari S: Survivin gene expression in early-stage non-small cell lung cancer. J Pathol 200: 620-626, 2003.
20. Lu B, Gonzalez A, Massion PP, Shyr Y, Shaktour B, Carbone DP and Hallahan DE: Nuclear survivin as a biomarker for non-small-cell lung cancer. Br J Cancer 91: 537-540, 2004.
21. Schneider PM, Praeuer HW, Stoeltzing O, Boehm J, Manning J, Metzger R, Fink U, Wegerer S, Hoelscher AH and Roth JA: Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer. Br J Cancer 83: 473-479, 2000.
22. Warnecke-Eberz U, Metzger R, Miyazono F, Baldus SE, Neiss S, Brabender J, Schaefer H, Doerfler W, Bollschweiler E, Dienes HP, Mueller RP, Danenberg PV, Hoelscher AH and Schneider PM: High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for predicition of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer. Clin Cancer Res 10: 3794-3799, 2004.
23. Warnecke-Eberz U, Hokita S, Xi H, Higashi H, Baldus SE, Metzger R, Brabender J, Bollschweiler E, Mueller RP, Dienes HP, Hoelscher AH and Schneider PM: Overexpression of survivin mRNA is associated with a favourable prognosis following neoadjuvant radiochemotherapy in esophageal cancer. Oncol Rep 13: 1241-1246, 2005.
24. LeBlanc M, Jacobson J and Crowley J: Partitioning and peeling for constructing prognostic groups. Stat Methods Med Res 11: 247-274, 2002.
25. Kaplan EL and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 187-220, 1958.
26. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Chemother Reps 50: 163-170, 1966.
27. Rosell R, Felip E, Garcia-Campelo R and Balana C: The biology of non-small-cell lung cancer: identifying new targets for rational therapy. Lung Cancer 46: 135-48, 2004.
28. Yamamoto T and Tanigawa N: The role of survivin as a new target of diagnosis and treatment in human cancer. Med Electron Microsc 34: 207-212, 2001.
29. Ambrosini G, Adida C, Sirugo G and Altieri DC: Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem 273: 11177-11182, 1998.
30. Ambrosini G, Adida C and Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3: 917-921, 1997.
31. Hattori M, Sakamoto H, Satoh K and Yamero T: DNA demethylase is expressed in ovarian cancers and the expression correlates with demethylation of CpG sites in the promoter region of c-erbB-2 and survivin genes. Cancer Lett 169: 155-164, 2001.
32. Yang L, Cao Z, Li F, Post DE, Van Meir EG, Zhong H and Wood WC: Tumor-specific gene expression using the survivin promoter is further increased by hypoxia. Gene Ther 11: 1215-1223, 2004.
33. Xu Y, Fang F, Ludewig G, Jones G and Jones D: A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. DNA Cell Bio 23: 527-537, 2004.
34. Atikcan S, Unsal E, Demirag F, Koksal D and Yilmaz A: Correlation between survivin expression and prognosis in non-small cell lung cancer. Respir Med 100: 2220-2226, 2006.
35. Bria E, Visca P, Novelli F, Casini B, Diodoro MG, Perrone-Donnorso R, Botti C, Sperduti I, Facciolo F, Milella M, Cecere FL, Cognetti F and Mottolese M: Nuclear and cytoplasmic cellular distribution of survivin as survival predictor in resected non-small-cell lung cancer. Eur J Surg Oncol: Epub ahead of print, Aug 9 2007.
36. Vischioni B, van der Valk P, Span SW, Kruyt FA, Rodriguez JA and Giaccone G: Nuclear localization of survivin is a positive prognostic factor for survival in advanced non-small-cell lung cancer. Ann Oncol 15: 1654-1660, 2004.
37. Chen YQ, Li DM, Cai YY, Liu C, Xia XM and Hu JF: The expression of survivin messenger RNA in sputum and cancerous tissue in human lung cancer. Zhonghua Jie He He Hu Xi Za Zhi 28: 225-229, 2005 (In Chinese).
38. Kennedy TC and Hirsch FR: Using molecular markers in sputum for the early detection of lung cancer: a review. Lung Cancer 45(Suppl 2): 21-27, 2004.
39. Hoffmann AC, Warnecke-Eberz U, Luebke T, Prenzel K, Metzger R, Heitmann M, Neiss S, Vallbohmer D, Hoelscher AH and Schneider PM: Survivin mRNA in peripheral blood is frequently detected and significantly decreased following resection of gastrointestinal cancers. J Surg Oncol 95: 51-54, 2007.
40. Dong DQ, Yang YH, Xue DY and Feng XJ: Expression of survivin mRNA of sputum and pleural effusions in human lung cancer. Zhong Nan Da Xue Xue Bao Yi Xue Ban 31: 848-852, 2006 (in Chinese).